These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 28150213)
21. Harnessing Dendritic Cells for Poly (D,L-lactide- Koerner J; Horvath D; Groettrup M Front Immunol; 2019; 10():707. PubMed ID: 31024545 [TBL] [Abstract][Full Text] [Related]
22. Enhanced presentation of MHC class Ia, Ib and class II-restricted peptides encapsulated in biodegradable nanoparticles: a promising strategy for tumor immunotherapy. Ma W; Smith T; Bogin V; Zhang Y; Ozkan C; Ozkan M; Hayden M; Schroter S; Carrier E; Messmer D; Kumar V; Minev B J Transl Med; 2011 Mar; 9():34. PubMed ID: 21450109 [TBL] [Abstract][Full Text] [Related]
23. Engineered artificial antigen presenting cells facilitate direct and efficient expansion of tumor infiltrating lymphocytes. Ye Q; Loisiou M; Levine BL; Suhoski MM; Riley JL; June CH; Coukos G; Powell DJ J Transl Med; 2011 Aug; 9():131. PubMed ID: 21827675 [TBL] [Abstract][Full Text] [Related]
24. An antigen-specific semi-therapeutic treatment with local delivery of tolerogenic factors through a dual-sized microparticle system blocks experimental autoimmune encephalomyelitis. Cho JJ; Stewart JM; Drashansky TT; Brusko MA; Zuniga AN; Lorentsen KJ; Keselowsky BG; Avram D Biomaterials; 2017 Oct; 143():79-92. PubMed ID: 28772190 [TBL] [Abstract][Full Text] [Related]
25. Toll-like receptor 3-induced immune response by poly(d,l-lactide-co-glycolide) nanoparticles for dendritic cell-based cancer immunotherapy. Han HD; Byeon Y; Kang TH; Jung ID; Lee JW; Shin BC; Lee YJ; Sood AK; Park YM Int J Nanomedicine; 2016; 11():5729-5742. PubMed ID: 27843314 [TBL] [Abstract][Full Text] [Related]
26. Artificial antigen-presenting cells are superior to dendritic cells at inducing antigen-specific cytotoxic T lymphocytes. Shao J; Xu Q; Su S; Wei J; Meng F; Chen F; Zhao Y; Du J; Zou Z; Qian X; Liu B Cell Immunol; 2018 Dec; 334():78-86. PubMed ID: 30392890 [TBL] [Abstract][Full Text] [Related]
27. PLGA nanoparticle-mediated delivery of tumor antigenic peptides elicits effective immune responses. Ma W; Chen M; Kaushal S; McElroy M; Zhang Y; Ozkan C; Bouvet M; Kruse C; Grotjahn D; Ichim T; Minev B Int J Nanomedicine; 2012; 7():1475-87. PubMed ID: 22619507 [TBL] [Abstract][Full Text] [Related]
28. Nanoscale artificial antigen presenting cells for T cell immunotherapy. Perica K; De León Medero A; Durai M; Chiu YL; Bieler JG; Sibener L; Niemöller M; Assenmacher M; Richter A; Edidin M; Oelke M; Schneck J Nanomedicine; 2014 Jan; 10(1):119-29. PubMed ID: 23891987 [TBL] [Abstract][Full Text] [Related]
29. Immunotherapy for Tumor Metastasis by Artificial Antigen-Presenting Cells via Targeted Microenvironment Regulation and T-Cell Activation. Lu Y; Li L; Du J; Chen J; Xu X; Yang X; Ding C; Mao C ACS Appl Mater Interfaces; 2021 Dec; 13(47):55890-55901. PubMed ID: 34787393 [TBL] [Abstract][Full Text] [Related]
30. Polymer nanoparticles for enhanced immune response: combined delivery of tumor antigen and small interference RNA for immunosuppressive gene to dendritic cells. Heo MB; Cho MY; Lim YT Acta Biomater; 2014 May; 10(5):2169-76. PubMed ID: 24394635 [TBL] [Abstract][Full Text] [Related]
31. Artificial antigen presenting cell (aAPC) mediated activation and expansion of natural killer T cells. East JE; Sun W; Webb TJ J Vis Exp; 2012 Dec; (70):. PubMed ID: 23299308 [TBL] [Abstract][Full Text] [Related]
32. Biodegradable microparticles loaded with doxorubicin and CpG ODN for in situ immunization against cancer. Makkouk A; Joshi VB; Wongrakpanich A; Lemke CD; Gross BP; Salem AK; Weiner GJ AAPS J; 2015 Jan; 17(1):184-93. PubMed ID: 25331103 [TBL] [Abstract][Full Text] [Related]
33. Biodegradable nanoparticle mediated antigen delivery to human cord blood derived dendritic cells for induction of primary T cell responses. Diwan M; Elamanchili P; Lane H; Gainer A; Samuel J J Drug Target; 2003; 11(8-10):495-507. PubMed ID: 15203918 [TBL] [Abstract][Full Text] [Related]
34. Artificial antigen-presenting cells plus IL-15 and IL-21 efficiently induce melanoma-specific cytotoxic CD8+ CD28+ T lymphocyte responses. Yu X; He J; Mongkhoune S; Peng Y; Xie Y; Su J; Zhou SF; Xie XX; Luo GR; Fang Y; Li X; Li X; Zhou N; Zhao YX; Lu XL Asian Pac J Trop Med; 2013 Jun; 6(6):467-72. PubMed ID: 23711708 [TBL] [Abstract][Full Text] [Related]
35. Peptide-beta2-microglobulin-major histocompatibility complex expressing cells are potent antigen-presenting cells that can generate specific T cells. Obermann S; Petrykowska S; Manns MP; Korangy F; Greten TF Immunology; 2007 Sep; 122(1):90-7. PubMed ID: 17472719 [TBL] [Abstract][Full Text] [Related]
36. PLGA-Listeriolysin O microspheres: Opening the gate for cytosolic delivery of cancer antigens. Gilert A; Baruch L; Bronshtein T; Machluf M Biomed Microdevices; 2016 Apr; 18(2):23. PubMed ID: 26888439 [TBL] [Abstract][Full Text] [Related]
37. 4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy. Zhang H; Snyder KM; Suhoski MM; Maus MV; Kapoor V; June CH; Mackall CL J Immunol; 2007 Oct; 179(7):4910-8. PubMed ID: 17878391 [TBL] [Abstract][Full Text] [Related]
38. Activation of antigen-specific T cell-responses by mannan-decorated PLGA nanoparticles. Hamdy S; Haddadi A; Shayeganpour A; Samuel J; Lavasanifar A Pharm Res; 2011 Sep; 28(9):2288-301. PubMed ID: 21560020 [TBL] [Abstract][Full Text] [Related]
39. pH-Responsive Poly(D,L-lactic-co-glycolic acid) Nanoparticles with Rapid Antigen Release Behavior Promote Immune Response. Liu Q; Chen X; Jia J; Zhang W; Yang T; Wang L; Ma G ACS Nano; 2015 May; 9(5):4925-38. PubMed ID: 25898266 [TBL] [Abstract][Full Text] [Related]
40. Particle-Based Artificial Antigen-Presenting Cell Systems for T Cell Activation in Adoptive T Cell Therapy. Hou F; Guo Z; Ho MT; Hui Y; Zhao CX ACS Nano; 2024 Mar; 18(12):8571-8599. PubMed ID: 38483840 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]